DeciBio Intelligence Portal
DeciBio Intelligence Portal

Precision insights,
delivered on demand.

One portal, grounded in DeciBio's primary research. DeciChat, our AI synthesis layer, turns that research into a sourced answer in minutes. Every answer cited. Every source verifiable.

15+
Market Reports
200+
Precision Medicine KOL Transcripts
1,600+
DxBook Survey Entries
15+
Markets Covered
HOW IT WORKS

One question reaches every source at once.

DeciChat searches DeciBio's market reports, KOL interview transcripts, and lab-level DxBooks data together — quantitative and qualitative in the same answer. Open the dashboard behind a number, or the transcript behind a theme.

Foundation

The research every answer is built on.

Every report, dataset, and transcript comes from research DeciBio ran directly.

MARKET
REPORTS

Market Reports

Market sizing, growth forecasts, and competitive landscapes, all built from primary research. The evidence base for market-entry decisions, portfolio prioritization, and board-level strategy.

Browse reports →
DXBOOKS

DxBooks

Structured, continuously updated views of competitor positioning and technology adoption across oncology NGS, infectious disease, and digital pathology. See where share is moving before your next planning cycle.

Explore DxBooks →
TRANSCRIPT
DATABASE

Transcript Database

200+ interviews and counting with the end users your market depends on. Unfiltered, and useful for pressure-testing strategy against what the field actually says.

Search transcripts →
POWERED BY DECICHAT

DeciChat turns that research into an answer

Ask one question and DeciChat pulls the context from a market report, the number from a DxBook, and what practitioners are actually saying from the transcripts — combined into a single answer, with every piece linked to its source.

Explore DeciChat →
liquid biopsy reimbursement pressure in 2026
Reimbursement pressure is concentrating in payer-driven markets, where competitive entry has turned pricing into the lead negotiating lever [1]. DxBook entries show list-price compression among the leading assays year over year [2], and KOLs interviewed in H1 2026 flag continued pressure as a 2027 planning assumption [3–8].
Market Report + 6 Transcripts + DxBook 1 cited answer

Bring us a question you're stuck on.

A live DeciChat session on the markets you compete in, answering the questions your team is working right now.

Request a Demo

Bring us a question you're stuck on.

A live DeciChat session on the markets you compete in, answering the questions your team is working right now.
Request Demo